Literature DB >> 22377186

Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases.

R Koivisto-Korander1, J I Martinsen, E Weiderpass, A Leminen, E Pukkala.   

Abstract

OBJECTIVES AND STUDY
DESIGN: Uterine sarcomas are an uncommon and heterogeneous group of malignancies. Their etiology is mainly unknown. Here, we analyzed trends in incidence and occupational variation in risk of uterine leiomyosarcomas (LMS) and endometrial stromal sarcomas (ESS) in the Nordic countries aided by NORDCAN and NOCCA (Nordic Occupational Cancer) databases. MAIN OUTCOME MEASURES: Incidence rates per 100,000 and Standardized incidences rates (SIR) obtained from NORDCAN and NOCCA databases.
RESULTS: The incidence rates were about 0.3 per 100,000 for ESS and about 0.4 per 100,000 for LMS in Denmark, Finland, Iceland, and Norway. During the study-period (1978-2007), the incidence rates in each country were quite similar and constant. The age-specific incidence of LMS showed a peak around menopause. Significantly increased risk for LMS occurred in shoe and leather workers, farmers and teachers, whereas significantly low risk was detected with packers in the NOCCA data from Finland, Norway, and Sweden. For ESS no occupations showed either increased or decreased incidences.
CONCLUSIONS: The incidence trends of LMS and ESS in our study were constant in four Nordic countries over time. The elevated risk for LMS with women exposed to leather work and animal dust indicates further exploration.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22377186     DOI: 10.1016/j.maturitas.2012.01.021

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  22 in total

1.  Uterine leiomyosarcomas with osteoclast-like giant cells associated with high expression of RUNX2 and RANKL.

Authors:  Mika Terasaki; Yasuhiro Terasaki; Kyoko Wakamatsu; Naomi Kuwahara; Koichi Yoneyama; Rieko Kawase; Keisuke Kurose; Etsuko Toda; Yoko Endo; Shinobu Kunugi; Yusuke Kajimoto; Akira Shimizu
Journal:  Virchows Arch       Date:  2021-01-06       Impact factor: 4.064

Review 2.  Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.

Authors:  Martee L Hensley; Brigitte A Barrette; Klaus Baumann; David Gaffney; Anne L Hamilton; Jae-Weon Kim; Johanna U Maenpaa; Patricia Pautier; Nadeem Ahmad Siddiqui; Anneke M Westermann; Isabelle Ray-Coquard
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

3.  Fertility and Pregnancy Outcome after Myoma Enucleation by Minilaparotomy under Microsurgical Conditions in Pronounced Uterus Myomatosus.

Authors:  K Floss; G-J Garcia-Rocha; S Kundu; C S von Kaisenberg; P Hillemanns; C Schippert
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-01       Impact factor: 2.915

4.  Practice Patterns and Complications of Benign Hysterectomy Following the FDA Statement Warning Against the Use of Power Morcellation.

Authors:  Francesco Multinu; Jvan Casarin; Kristine T Hanson; Stefano Angioni; Andrea Mariani; Elizabeth B Habermann; Shannon K Laughlin-Tommaso
Journal:  JAMA Surg       Date:  2018-06-20       Impact factor: 14.766

5.  Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Authors:  Dominik Denschlag; Sven Ackermann; Marco Johannes Battista; Wolfgang Cremer; Gerlinde Egerer; Markus Follmann; Heidemarie Haas; Philipp Harter; Simone Hettmer; Lars-Christian Horn; Ingolf Juhasz-Boess; Karin Kast; Günter Köhler; Thomas Kröncke; Katja Lindel; Peter Mallmann; Regine Meyer-Steinacker; Alexander Mustea; Edgar Petru; Peter Reichardt; Dietmar Schmidt; Hans-Georg Strauss; Clemens Tempfer; Falk Thiel; Uwe Ulrich; Thomas Vogl; Dirk Vordermark; Paul Gass; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

6.  Malignant tumors of the female reproductive system.

Authors:  Elisabete Weiderpass; France Labrèche
Journal:  Saf Health Work       Date:  2012-08-30

7.  Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.

Authors:  Netta Mäkinen; Mervi Aavikko; Tuomas Heikkinen; Minna Taipale; Jussi Taipale; Riitta Koivisto-Korander; Ralf Bützow; Pia Vahteristo
Journal:  PLoS Genet       Date:  2016-02-18       Impact factor: 5.917

8.  The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consortium.

Authors:  A S Felix; L S Cook; M M Gaudet; T E Rohan; L J Schouten; V W Setiawan; L A Wise; K E Anderson; L Bernstein; I De Vivo; C M Friedenreich; S M Gapstur; R A Goldbohm; B Henderson; P L Horn-Ross; L Kolonel; J V Lacey; X Liang; J Lissowska; A Magliocco; M L McCullough; A B Miller; S H Olson; J R Palmer; Y Park; A V Patel; J Prescott; R Rastogi; K Robien; L Rosenberg; C Schairer; X Ou Shu; P A van den Brandt; R A Virkus; N Wentzensen; Y-B Xiang; W-H Xu; H P Yang; L A Brinton
Journal:  Br J Cancer       Date:  2013-01-24       Impact factor: 7.640

9.  Endometrial Stromal Nodule: A Rarity and a Pathological Challenge.

Authors:  Camilla Skovvang Borg; Peter Humaidan; Hanne Noer; Huda Galib Majeed
Journal:  Case Rep Obstet Gynecol       Date:  2015-06-28

10.  Can proliferation biomarkers reliably predict recurrence in World Health Organization 2003 defined endometrial stromal sarcoma, low grade?

Authors:  Weiwei Feng; Anais Malpica; Ivar Skaland; Einar Gudlaugsson; Stanley J Robboy; Ingvild Dalen; Keqin Hua; Xianrong Zhou; Jan P A Baak
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.